Home » Reports » Broker Ratings » Hikma Pharmaceuticals Plc 6.7% Potential Decrease Indicated by Barclays Capital

Hikma Pharmaceuticals Plc 6.7% Potential Decrease Indicated by Barclays Capital

Hikma Pharmaceuticals Plc with EPIC/TICKER (LON:HIK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘EQUAL WEIGHT’ this morning by analysts at Barclays Capital. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Barclays Capital have set their target price at 1900 GBX on its stock. This is indicating the analyst believes there is a potential downside of -6.7% from the opening price of 2036 GBX. Over the last 30 and 90 trading days the company share price has increased 234 points and increased 332.5 points respectively. The 1 year high for the stock price is 2089 GBX while the 52 week low for the stock is 1491.5 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 1,816.96 GBX and a 200 Day Moving Average share price is recorded at 1,749.51. There are currently 242,278,486 shares in issue with the average daily volume traded being 626,654. Market capitalisation for LON:HIK is £4,981,245,672 GBP.